ABT-414采用Seagen的ADC技术,经vc可裂解linker偶联到MMAF毒素,抗体部分靶向EGFR CR1的一个隐藏表位,该表位在异常增殖的肿瘤细胞中暴露,因此该ADC主要聚集在肿瘤组织中。 可惜的是,艾伯维两项ADC先后失败,ABT-414(通用名Depatuxizumab Mafodotin)重点探索GBM,结果在GBM三期临床中未达到主要终点,以失败告终。 国内方面...
[3]. Zhang L, Ma Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-hu...
· ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope(2016); · Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy(2019); · Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combi...
资料4、WO2023028548 - BISPECIFIC TETRAVALENT ANTIBODY TARGETING EGFR AND HER3 资料5、BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study 声明:以上内容仅供参考,...
·ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope(2016); ·Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy(2019); ·Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining...
[10] L. Zhang, Y. Ma, Y. Zhao, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 2023 ASCO Abstract 3001. ...
[10] L. Zhang, Y. Ma, Y. Zhao, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 2023 ASCO Abstract 3001.[11] L. Zhang, Y. Ma, Y....
ADC药物兼具靶向和细胞毒药物双重抗肿瘤作用,多个靶点的ADC药物均在EGFR-TKI耐药人群显示了令人鼓舞的初步疗效数据,例如靶向TROP2、HER-3、HER3/EGFR以及c-MET的ADC药物在EGFR-TKI耐药人群均显示了极具前景的初步疗效,目前多项随机对照的III...
[10] L. Zhang, Y. Ma, Y. Zhao, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 2023 ASCO Abstract 3001. ...
[1]Li Zhang, Yuxiang Ma,et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.presented at ASCO 2023. ...